Tag: Abionyx
ABIONYX Pharma – Bpifrance supports the development of CER-001 in ophthalmology with non-dilutive innovation aid of around 1 million euros – 03/14/2024 at 6:00 p.m.
• Validation of the development of CER-001 in ophthalmology• Key step to launch a clinical study in a new severe indication Toulouse, FRANCE, Lakeland, UNITED STATES, March 14, 2024, 6:00…
Abionyx Pharma: will benefit from aid from 1ME from Bpifrance
(CercleFinance.com) – Abionyx Pharma announces innovation aid of nearly 1 million euros from Bpifrance. The purpose of this aid is to support the drug candidate CER-001 dedicated to the treatment…
Abionyx Pharma receives nearly 1 million euros from Bpifrance
(AOF) – Abionyx Pharma announces that it is the beneficiary of innovation aid of nearly 1 million euros from Bpifrance. The biotech specialist in innovative therapies based on the only…
Abionyx Pharma: will benefit from 1ME aid from Bpifrance – 03/14/2024 at 6:20 p.m.
Member Login Customer Login (CercleFinance.com) – Abionyx Pharma announces innovation aid of nearly 1 million euros from Bpifrance. The purpose of this aid is to support the drug candidate CER-001…
Abionyx Pharma receives nearly 1 million euros from Bpifrance – 03/14/2024 at 6:21 p.m.
(AOF) – Abionyx Pharma announces that it is the beneficiary of innovation aid of nearly 1 million euros from Bpifrance. The biotech specialist in innovative therapies based on the only…
Abionyx: reduction in net loss in 2023 – 03/11/2024 at 1:55 p.m.
(CercleFinance.com) – Abionyx Pharma publishes a net loss of 3.52 million euros for 2023, compared to a deficit of 4.21 million the previous year, as well as a 20% reduction…
ABIONYX Pharma announces its 2023 annual results – 03/11/2024 at 07:30
• 20% reduction in annual operational loss • Cash of €4.1 million as of December 31, 2023 Toulouse, FRANCE, Lakeland, UNITED STATES, March 11, 2024, 7:30 a.m. CET – ABIONYX…
Abionyx Pharma: 2024 financial agenda
A.S. Published on 03/10/2024 at 5:31 p.m. Photo credit © Abionyx Pharma (Boursier.com) — Abionyx…
ABIONYX Pharma announces its financial communication calendar for the 2024 financial year – 03/07/2024 at 7:00 p.m.
Toulouse, FRANCE, Lakeland, UNITED STATES, March 7, 2024, 7:00 p.m. – ABIONYX Pharma, (FR0012616852 – ABNX – PEA PME eligible), new generation biotechnology company dedicated to the discovery and development…
Abionyx Pharma posts 4.1 million euros in cash at the end of 2023 – 02/29/2024 at 6:38 p.m.
(AOF) – Abionyx Pharma records consolidated turnover of 4.64 million euros for the 2023 financial year compared to 5.25 million euros in 2022. Its cash position amounts to 4.1 million…
ABIONYX Pharma provides an update on its activity and cash position for the 4th quarter of 2023 – 02/29/2024 at 7:00 p.m.
• 2023 consolidated turnover of €4.6 million net of studies for ABIONYX• Cash of €4.1 million as of December 31, 2023 Toulouse, FRANCE, Lakeland, UNITED STATES, February 29, 2024, 6:00…
Abionyx Pharma posts 4.1 million euros in cash at the end of 2023
(AOF) – Abionyx Pharma records consolidated turnover of 4.64 million euros for the 2023 financial year compared to 5.25 million euros in 2022. Its cash position amounts to 4.1 million…